Patient Support Hotline

Call (844) 244-1309

ZERO360 is a free, comprehensive patient support service to help patients and their families navigate insurance and financial obstacles to cover treatment and other critical needs associated with cancer.


Subscribe to our E-Newsletter

Stay up-to-date on the latest news about prostate cancer. Join our distribution list to receive periodic email updates and our monthly e-newsletter.

  • Patient Support (844) 244-1309
  • Search
  • e-News Signup Enews Signup
  • Run/Walk
  • Donate

Hot SHEET 2020

Made possible by charitable contributions from

Clovis Oncology

 – Thank You!


Our monthly newsletter, the Hot SHEET, highlights the latest in treatment strategies as well as emerging treatments. The Hot SHEET is distributed free at chapter support group meetings, and is available in PDF on the Us TOO web site.

Subscribe to get the Hot SHEET (and other prostate cancer news and information) for free via email from Us TOO at www.ustoo.org/subscribe.

Hot SHEET Personal Subscriptions Now Available

If you are unable to attend chapter meetings to get the latest issue or prefer an original copy, we can deliver the newsletter right to your home or office. Download and print a subscription order form or order online.

  • Pembrolizumab Shows Limited Activity Against Prostate Cancer
  • When the Going Gets Tough… How to Help Yourself or a Friend
  • Olaparib in Patients with Metastatic Castrate-Resistant Prostate Cancer
  • Impact of Age at Diagnosis of De Novo Metastatic Prostate Cancer
  • Clinical Utility of a Genomic Classifier In Men Undergoing RP
  • Doc Moyad's No Bogus Science Column: "2020—The Year of the Statin & Elvis?!"
  • Variation in the Prescription of Androgen Deprivation Therapy
  • The Role of Hypofractionated Radiotherapy for Localized PCa
  • New Tools May ID Intermediate-Risk PCa Patients Suitable for AS
  • Index of Articles Published in 2019 Us TOO Hot SHEETs
  • Chemo Triumphs in Second Line Metastatic Prostate Cancer
  • Salvage RT First Found Superior for Post-RP PSA Failure
  • Tailored Pelvic PT May Curb Post-RP Incontinence & Pain
  • AS, RP, EBRT or Brachytherapy With or Without ADT
  • Doc Moyad's No Bogus Science Column: "Resistance Training!?"
  • Extended Pelvic Lymph Node Dissection & PCa Outcomes
  • More Veggies No Help in AS
  • Outcomes of Hypofractionated/ Conventionally Fractionated RT
  • Anterior-Dominant PCa Harder to Detect Than Other Locations
  • Impact of MRI & Targeted Biopsies on Eligibility for Surveillance
  • Implications of Germline Genetic Testing in Prostate Cancer
  • Tumor-Associated Release of Prostatic Cells After Biopsies


  • Lower Out-of-Pocket Costs for Robotic Cancer Surgery
  • More Radium-223 in mCRPC Means More Toxicity
  • Stalling ADT Use in Recurrent PCa
  • Validation of Gallium-68 PSMA PET/CT for Primary PCa Staging
  • Long-Term Follow-Up in Low-Dose-Rate Brachytherapy for PCa
  • Doc Moyad's No Bogus Science: "Lorcaserin Bites the Dust!?"
  • Apalutamide & Overall Survival in Non-Metastatic CRPC
  • Pembrolizumab for Treating Refractory Metastatic CRPC
  • PET Spots Prostate Cancer Metastases Missed on CT, MRI
  • Modest Survival Gains Shown in Newly Diagnosed Metastatic PCa
  • Long-Term Outcomes in Gleason Grades 2 & 3 PCa with AS
  • Guest Column: Staying Sexually Active After PCa Treatment
  • Earlier Cabazitaxel Use in mCRPC
  • FDA Panel Thumbs Down for Cancer Focal Therapy
  • Apalutamide Benefit Sustained in Metastatic Castrate-Sensitive PCa
  • Hypofractionate RT for PCa Stands the Test of Time
  • Enzalutamide, ADT and Salvage RT in High-Risk PSA-Recurrent PCa
  • Robotic-Assisted RP & Persistent Postoperative Opioid Use
  • Doc Moyad's No Bogus Science: "Heart Healthy = Immune Healthy = Prostate Healthy!?"
  • The Cost of Bottling Up Emotions
  • Sunitinib, Docetaxel & Prednisone in Chemo-Naïve Metastatic CRPC
  • Less Frequent Prostate Cancer Screening a Good Idea
  • Guest Column: Goodbye Poke and Hope!
  • HSD3B1 Genotype Tied to Prostate Cancer Outcomes


  • Defining a Role for Immunotherapy in mCRPC
  • Veteran’s Health Bill Promotes Comprehensive PCa Care Program
  • Prostatectomy of Mixed Mortality Benefit in Men with Prostate Cancer
  • Long-Term Unmet Supportive Care Needs of Prostate Cancer Survivors
  • AS vs. Immediate Treatment – Financial Incentives for Urologists
  • Doc Moyad’s No Bogus Science: “Are Low-Carb Diets Groovy Now!?”
  • Combined Biopsy Strategy Improved Prostate Cancer Diagnosis
  • 177Lu-PSMA Radionuclide Treatment in Men with Metastatic CRPC
  • PSMA PET/CT Better Detects Prostate Cancer Spread
  • Genomic Prostate Score Does Not Improve Risk Assessment
  • Its a Bust Adding Immunotherapy No Benefit in mCRPC
  • Time to Reassess Risks of Active Surveillance in Prostate Cancer?
  • Too Much RT Still Being Used for Bone Metastases
  • Randomized Trial of Conventional vs. Hypofractionated IMRT
  • Shared Decision Making & PSA-Based PCa Screening
  • Genomic Prostate Score (GPS) Results in the Canary AS Study
  • Doc Moyad's No Bogus Science Column: "Intrusive Thoughts?"
  • RP Without Pelvic Lymph Node Dissection is Widely Practiced
  • Guest Column: Options for Urinary Incontinence After PCa Treatment
  • Darolutamide & ADT vs. ADT Alone in Non-Metastatic CRPC
  • Prostate SBRT Shows Positive Outcomes in Treatment of Low and Intermediate-Risk Disease


  • Oral ADT Slashes Heart Risk in Advanced Prostate Cancer
  • Studies in Hormonal Therapy for Non-Metastatic CRPC (nmCRPC)
  • Testosterone Therapy Does Not Increase PSA Recurrence or Death
  • PCa Incidence 5 Years After USPSTF Nix on PCa Screening
  • Olaparib for Metastatic Castration-Resistant Prostate Cancer
  • Doc Moyad's No Bogus Science Column: "PSA = People-Specific Antigen?!"
  • Consider Genetic Testing in All Metastatic Prostate Cancers
  • 18F-Fluciclovine PET in Men with BCR of Prostate Cancer After RP
  • PCa Trial Participants Shown to Be Overwhelmingly White
  • Benefit and Costs for Abiraterone vs. Enzalutamide in mCRPC
  • Post-Diagnosis BMI, Weight Gain & Mortality in Nonmetastatic PCa
  • Risk of PCa-Associated with Hereditary Cancer Syndromes
  • Prostate Cancer Mortality, Treatment in the US Differs by Region
  • BRCA2 Mutations Have Stronger Link to Cancer Than BRCA1
  • Benefits for PSA Test Screening Greater Than Generally Recognized
  • Enzalutamide and Survival in Non-metastatic CRPC
  • GNRH Antagonist vs. Agonist for Metastatic Prostate Cancer
  • Doc Moyad's No Bogus Science: "Parking Fees at Cancer Centers!?"
  • New Focus on ADT in Prostate Cancer Guideline
  • Evaluation of Shorter RT Regimens for Breast & Prostate Cancers
  • Post-Dx BMI, Weight Change, PCa Mortality & Cardiovascular Disease
  • Cryotherapy – An Effective Treatment for Intermediate-Risk PCa?


  • A Call to Test Men with Prostate Cancer for COVID-19
  • Quality of Life Takes Huge Hit After Prostate Cancer Treatment
  • Genomic Profiles of PCa in Men of African and European Ancestry
  • Beyond PSA: New Prostate Cancer Screening Options
  • Doc Moyad's No Bogus Science: "Weighing in on Weight Issues?!"
  • Can Grape Seed Extract Slow Prostate Cancer Spread?
  • Gleason Grade Group 2 Intermediate Risk Prostate Cancer
  • Development & Validation of a Deep Learning Algorithm for Biopsies
  • Proof-of-Concept Study of Vaccine Shows Promise in Advanced PCa
  • Immune Checkpoint Inhibitors for PCa: Niche Role or Breakthrough?
  • RP with or without Neoadjuvant Chemohormonal Therapy in PCa
  • ADT & Favorable Intermediate-Risk PCa
  • Surgery Rates Doubled for High-Risk PCa
  • Less AS is Feasible with Some PCa
  • Racial Disparities for Men with PCa Post-RP
  • Rucaparib in mCRPC with BRCA1 or 2
  • Doc Moyad's No Bogus Science Column: "A Supplement & CIPN = Yikes?!"
  • Under Treatment of PCa in Rural Locations
  • PCa & Bone Marrow Fatty Cells
  • Canary AS Study: MRI & High-Grade PCa
  • Prostate Mapping for US-Guided Biopsies
  • Delay by COVID-19 & RP Outcome?
  • HIFU Hemigland Ablation for PCa
  • House VA Committee Promotes PCa Care
  • Urine Extracellular Vesicle GATA2 mRNA
  • Oral Antiandrogens & Risk of Dementia
  • Darolutamide & Mortality for Men with PCa
  • Prostate Cancer in Young Men
  • Hold Off Radiotherapy After Prostate Cancer Surgery
  • Low BMD Testing Rates After Andro-gen Deprivation Therapy for PCa
  • A New AKT Inhibitor for PCa
  • Reserve PARP Inhibitors for Treating mCRPC with BRCA Mutations
  • Doc Moyad's No Bogus Science: "Vote for Jicama – I Love Jicama!"
  • Black Men with PCa Found to Be Reluctant to Participate in Trials
  • Negative Trial Shows Overall Survival Benefit in mCRPC
  • Prognostic Impact of Intraductal Carcinoma of the Prostate (ICP)
  • More Prostate Cancers are Being Diagnosed at a Later Stage
  • Impact of Biopsy Compliance on AS Outcomes for PCa Patients
  • Adjuvant ADT Best in Localized PCa Say Pooled Data
  • New PCa Staging System May Improve Pretreatment Prognostication
  • Active Surveillance for Black vs. White
  • Focal RT Boost in High-Risk PCa Cuts Biochemical Relapse Rate
  • Doc Moyad’s No Bogus Science: "Kiwi Rules!?"
  • Fall & Fracture Risk with Androgen Receptor Inhibitors (ARI) Treatment
  • Hood Technique & Post-RP Urinary Incontinence
  • Multiple Negative Prostate Biopsies in Men on Active Surveillance
  • Could Ipilimumab Have Benefit in Metastatic PCa After All?
  • SBRT Doubles Pain Response Over Usual RT in Spinal Metastases